论文部分内容阅读
目的 :研究植入式导管药盒系统 (PCS)在肝癌介入治疗中的应用价值。方法 :2 2 9例介入治疗的原发性肝癌病例按不同介入治疗方法分为TACE组、PCS组和TAI组。对三组疗效和方法进行了对比分析。结果 :PCS组缓解率虽然与TAI组无显著差异 ,但 1,2年生存率却明显高于TAI组。但随着时间推移 ,生存率下降显著 ,与TAI的差异逐渐缩小 ,3年生存率两组已无明显差异 ,而TACE与上述两组的差异却越来越明显。结论 :PCS在不能栓塞的肝癌介入治疗中有较好的应用价值。髂外动脉穿刺植入药盒优于股动脉及锁骨下动脉法
Objective: To study the value of implantable catheterization kit (PCS) in the interventional treatment of liver cancer. Methods: Twenty-two cases of primary liver cancer treated with interventional therapy were divided into TACE group, PCS group and TAI group according to different interventional methods. The effects and methods of the three groups were compared and analyzed. Results: Although the response rate of PCS group was not significantly different from that of TAI group, the 1-year survival rate was significantly higher than that of TAI group. However, with the passage of time, the survival rate decreased significantly, the difference with TAI gradually narrowed, and there was no significant difference in the three-year survival rate between the two groups. However, the difference between TACE and the above two groups was more and more obvious. Conclusion : PCS has a good application value in the interventional treatment of liver cancer that cannot be embolized. External iliac artery puncture implantation kit is better than femoral artery and subclavian artery method